Physician profile
David M Mozer
NPI 1013916840
$909.25
in general payments reported to CMS, 2019-2025
15 companies · $69.43 in 2025
The $69.43 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $44.62 · 2021: $168 · 2022: $160 · 2023: $119 · 2024: $215 · 2025: $69.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $188.48 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $100.56 | 2019-2023 | |
| Sanofi Pasteur INC. | $95.60 | 2019-2024 | |
| Corium, LLC | $89.36 | 2021-2023 | Azstarys |
| Sobi, INC | $73.53 | 2019-2023 | |
| Tris Pharma INC | $64.25 | 2020-2021 | |
| Glaxosmithkline, LLC. | $56.03 | 2019-2024 | Rotarix |
| Supernus Pharmaceuticals, INC. | $54.11 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $40.14 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $39.11 | 2019-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Adlon Therapeutics L.P. | $30.09 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $25.17 | 2024 | |
| Acadia Pharmaceuticals INC | $25.14 | 2024 | Daybue |
| Biomarin Pharmaceutical INC. | $13.93 | 2025 | Voxzogo 1.2mg |
| Mylan Pharmaceuticals INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mozer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.